PD-1/PD-L1 monoclonal antibodies have made breakthroughs in the treatment of many cancers in clinical, but there are still problems such as a high incidence of adverse reactions and a large range of treatment tolerance (44, 45). This evidence concerns the gene CD274 and cancer.